No headlines found.
Receipt of Delinquency Notification from Nasdaq
Globe Newswire (Mon, 1-Dec 4:30 PM ET)
Basel Medical Group Ltd provides general and subspecialized orthopedic, trauma and sports medicine services such as knee/hip replacements, sports medicine/surgery, spine surgery, foot/ankle surgery and minimally invasive orthopedic procedures, as well as neurosurgical treatments. The services provided by clinics include, but are not limited to, consultation, medical diagnosis and medical or surgical treatments for orthopedic, trauma, sports medicine, general practice, health screening, mental health, women's health and neurosurgical conditions and clinics are equipped with the facilities needed to perform a variety of procedures on site and minor surgical services. Key revenue is generated from Singapore.
Basel Medical Group - trades on the NASDAQ stock market under the symbol BMGL.
As of December 19, 2025, BMGL stock price declined to $0.72 with 30,507 million shares trading.
BMGL has a beta of -1.43, meaning it tends to be less sensitive to market movements. BMGL has a correlation of 0.01 to the broad based SPY ETF.
BMGL has a market cap of $13.53 million. This is considered a Sub-Micro Cap stock.
BMGL support price is $.68 and resistance is $.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BMGL shares will trade within this expected range on the day.
